GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a 140-week open-label, multi-center long-term extension study from GALLANT 9 to
monitor the safety and tolerability of oral tesaglitazar 0.5 mg and insulin in patients with
type 2 diabetes during up to 140 weeks of treatment. The total duration, including treatment
and follow-up, is 143 weeks.